Overview of Легендаль

The medicinal product Легендаль is defined by its core active ingredient, Lactulose, a synthetic disaccharide. It is clinically recognized and formally classified under two interconnected pharmacological classes: as an osmotic laxative and as an ammonium detoxicant.

Property	Description
Active ingredient	Lactulose
Form	Oral Solution, Syrup, Powder
Pharmacological class	Osmotic Laxative, Ammonium Detoxicant
General purpose	Relieves constipation and reduces ammonia in the blood
Origin	Synthetic disaccharide (derived from lactose)

Composition, Origin, and Differentiation

Lactulose, the basis of Легендаль, is a synthetic disaccharide composed of galactose and fructose. The compound’s non-absorbable nature is a defining characteristic, ensuring the single active component bypasses digestion in the small intestine to reach the colon intact. The product’s typical presentation as an oral solution or syrup facilitates easy oral intake. This synthetic origin is crucial because it dictates the substance's resistance to breakdown in the upper gastrointestinal tract, enabling it to fully engage in the colonic processes necessary for both its osmotic and detoxification effects.

General Purpose and Clinically Recognized Actions

The overall purpose of Легендаль is achieved through two distinct, medically recognized physiological actions. As an osmotic laxative, the Lactulose draws water into the intestine, facilitating stool softening and the promotion of natural bowel movements. Furthermore, its role as an ammonium detoxicant is critical: the disaccharide is fermented in the colon, leading to the trapping and subsequent elimination of toxic ammonia by converting it into the non-absorbable ammonium ion. This mechanism is specifically supported by pharmacological studies for its effectiveness in both improving digestive regularity and providing metabolic assistance. This dual function provides both reliable digestive support and assists in critical metabolic clearance.

Regulatory References

Lactulose: NIH StatPearls

What side effects are possible with Легендаль?

Possible Side Effects and Safety Information

The safety profile of Легендаль (Lactulose) is defined by officially documented adverse reactions, primarily involving the gastrointestinal system, and is categorized by frequency in regulatory sources. Diarrhoea is the most frequent reaction, classified as Very Common. Flatulence, abdominal pain, nausea, and vomiting are classified as Common effects.

Officially Documented Adverse Reactions by Frequency

Frequency Classification
Very Common (ge1/10)	Diarrhoea
Common (ge1/100 to <1/10)	Flatulence, Abdominal pain, Nausea, Vomiting
Uncommon (ge1/1,000 to <1/100)	Electrolyte imbalance due to diarrhoea
Not Known	Hypersensitivity reactions, Rash, Pruritus, Urticaria

Safety Considerations

Safety documentation emphasizes risks related to excessive dosage and specific patient populations. Prolonged or severe diarrhoea may lead to the serious adverse reactions of fluid loss and electrolyte imbalance (hypokalemia and hypernatremia). This risk necessitates periodic control of serum electrolytes for older or debilitated patients receiving treatment for more than six months.

Regulatory documents state that Легендаль is contraindicated in patients with galactosaemia (low galactose diet). Caution is noted for use in diabetics due to the presence of minor amounts of related sugars. Time-related patterns show that effects like flatulence and intestinal cramps are often transient and occur during the first few days of treatment. Safety restrictions also include a note concerning a theoretical procedural hazard during certain electrocautery procedures.

Overdose and Emergency Response

Overdose Manifestations

Overdose of Легендаль is primarily characterized by an exaggeration of the drug's osmotic effect, leading to excessive fluid movement in the gastrointestinal tract. The officially documented clinical presentations include persistent diarrhea and pronounced abdominal pain or cramps. Other reported manifestations include increased flatulence.

Severe Outcomes and Required Actions

The most serious potential complication documented in regulatory labeling is the resulting fluid and electrolyte disturbance. Prolonged, severe diarrhea can lead to clinically significant dehydration and critical hypokalemia (low potassium).

In the event of suspected overdose or the onset of severe, persistent symptoms, the regulatory requirement is the discontinuation of the drug. Patients must seek immediate medical attention for any signs of extensive fluid loss or severe electrolyte imbalance, as explicitly required by prescribing information.

Management and Antidote Information

Management is restricted to symptomatic and supportive treatment. This mandated care focuses on the correction of the metabolic effects, specifically through fluid and electrolyte replacement. No specific antidote is known for Легендаль overdose. Regulatory sources advise that caution is necessary for patients prone to developing electrolyte disorders, such as the elderly or those with impaired renal function, due to the heightened severity of risks associated with fluid loss.

Therapeutic Uses of Легендаль

Quick Facts

Therapeutic Domain
Management of high blood pressure (hypertension)
Used to decrease the risk of related events, such as stroke and heart attack

Therapeutic Overview of Легендаль

Легендаль is medically indicated for the management of high blood pressure, a condition also known as hypertension. Appropriate treatment of elevated blood pressure is a key element of disease management and is utilized to decrease the potential for serious health events.

Controlling blood pressure with this medication helps to alleviate the workload placed on the heart and arteries, which, over an extended period, can cause damage to blood vessels in essential organs such as the brain, heart, and kidneys. By facilitating the maintenance of blood pressure within a target range, the medication assists in reducing the risk of complications like stroke, heart failure, and kidney failure that are associated with chronic, uncontrolled hypertension. The medication is used as part of a comprehensive management strategy, which may also involve lifestyle modifications.

Eligibility and Restrictions for Use

The eligibility profile for this medicine is strictly defined by regulatory documents, distinguishing between absolute prohibitions and conditional permissions for specific patient populations.

Populations for whom use is Contraindicated: Patients must not use this medicine if they have Galactosaemia or require a low galactose diet, due to the drug's composition. Use is also prohibited in cases of gastrointestinal obstruction, digestive perforation or risk of perforation, acute inflammatory bowel disease (such as Crohn's disease or ulcerative colitis), or painful abdominal syndromes of undetermined cause.

Age and Special Population Eligibility: Adults and adolescents are generally permitted to use the medicine. Use in infants and children under 14 years is allowed for constipation, but only under explicit medical supervision. The medicine’s safety and efficacy for the hepatic encephalopathy indication are not established in the entire pediatric population. Use during pregnancy and lactation is permitted, as negligible systemic exposure is anticipated. No special dosage changes are required for patients with renal or hepatic impairment.

Eligibility-Related Restrictions: Caution is advised for diabetic patients, as high doses may affect blood glucose levels. Additionally, long-term use exceeding six months in elderly or debilitated patients necessitates periodic measurement of serum electrolytes, as stated in prescribing information.

What should I know about interactions with other medicines?

The regulatory documentation for Легендаль establishes an interaction profile defined primarily by local effects in the colon and additive risks related to electrolyte disturbance. These classifications are based strictly on official prescribing information.

Documented Interaction Restrictions

Restriction Category	Interacting Agents or Condition	Official Regulatory Statement
Contraindication	Low Galactose Diet (Galactosemia)	Formally prohibited due to the presence of trace galactose in the formulation.
Additive Pharmacodynamic Risk	Potassium-Losing Agents (e.g., Thiazides, Corticosteroids)	Co-administration may result in an additive loss of potassium, which increases the documented risk of hypokalaemia.
Increased Toxicity Risk	Cardiac Glycosides	The risk of hypokalaemia resulting from excessive fluid and electrolyte loss can potentiate the toxicity of these agents.

Efficacy and Monitoring Notes

The official label documents that certain non-absorbable agents may compromise the drug's function. Nonabsorbable Antacids may inhibit the intended reduction of colonic pH, potentially leading to a lack of desired therapeutic effect. Similarly, some oral anti-infective agents (such as Neomycin) may reduce efficacy by eliminating the colonic bacteria necessary for drug metabolism. No mandatory time-separation requirements for co-administration are documented. For elderly, debilitated patients receiving continuous treatment for over six months, the regulatory label mandates the periodic measurement of serum electrolytes (potassium, chloride, and carbon dioxide).

Mechanism of Action

How Легендаль Works: Mechanism of Action

Physical Mechanism: Colonic Osmotic Modulation

This domain explains the drug's purely physical action, which does not involve systemic absorption or interaction with human receptors. The non-absorbed disaccharide targets gastrointestinal luminal water, creating an osmotic gradient that draws water into the colon. This water influx physically increases the volume and alters the consistency of the colonic contents, which mechanically stimulates peristalsis (muscle contraction) and results in the acceleration of transit time.

Metabolic Mechanism: Acidification and Ion Trapping

This mechanism is dependent on the colonic commensal bacteria (microbiota) acting on the drug as a substrate through fermentation. This process generates Short-Chain Fatty Acids, which lower the colonic pH environment. The resulting acidic state is crucial for the trapping of ammonia ( NH3) by converting the absorbable NH3 into the non-absorbable ammonium ion ( NH4^+), resulting in the elimination of the ammonium ion with colonic contents.

Dosage and Administration Information

The administration of Легендаль (Lactulose) follows specific guidelines for its use as both a laxative and an ammonium detoxicant. The method of intake varies based on the condition being addressed and requires adherence to a response-driven dosing schedule.

Administration Routes and Preparation

Легендаль is approved for oral administration as a solution, syrup, or powder for reconstitution. For rapid effect or in severe cases of hepatic encephalopathy, the solution may also be administered via the rectal route. The oral solution can be administered undiluted or mixed with other liquids, such as water, milk, or fruit juice, to improve palatability. When using the powder, the packet contents must be fully dissolved in approximately 4 ounces of water prior to intake.

Dosing and Schedule

The standard adult starting dose for chronic constipation ranges from 15 to 30 mL (or 10 g to 20 g of lactulose) administered once daily. For the management of Portal-Systemic Encephalopathy (PSE), the dosing is significantly higher and must be titrated to a precise clinical endpoint: producing 2 to 3 soft stools per day. If a single daily dose is utilized, it is recommended to be taken at the same time each day.

Procedural Conditions

Patients undergoing therapy are advised to consume sufficient fluids (1.5 to 2 L) daily as part of the regimen. Due to the mechanism of action, an effect on bowel regularity may not be observed for 24 to 48 hours. Should adverse effects like diarrhea occur, the instruction is to immediately reduce the dosing regimen. No standard dose adjustments are specified for older adults or patients with renal or hepatic impairment.

Recent Clinical Evidence

Легендаль: Recent Clinical Evidence

Evidence for Use in Chronic Constipation

Легендаль was studied for the condition characterized by long-lasting constipation through various research designs, including short-term Randomized Controlled Trials (RCTs). These studies was evaluated in adults, pediatric patients, and older adults. The research examined outcomes related to physical discomfort and daily functioning, monitoring the change in spontaneous bowel movements (SBMs) per week and stool consistency. Studies explored changes in SBM frequency compared to placebo, and comparative studies monitored outcomes against other osmotic agents, with findings mixed across studies. The results apply only to the populations studied, and limited information for long-term outcomes remains an area of uncertainty.

Evidence for Use in Hepatic Encephalopathy (HE)

Легендаль was studied for the condition known as Hepatic Encephalopathy (HE) in adult patients with cirrhosis experiencing acute episodes and those needing prophylaxis (prevention of recurrence). Research examined outcomes such as blood ammonia concentration and neurological status using controlled trials. Findings describe patterns observed in the studies where participants receiving Lactulose was associated with measurements of blood ammonia concentration were reported, and studies report how symptoms evolved in the observed populations. Placebo-controlled trials for acute, overt HE are generally not feasible; therefore, research often involves comparisons to other active treatments.

Research Gaps and Limitations

The research on Легендаль highlights what is known — and what is still uncertain. Long-term effects are not fully established for both constipation and HE, as many pivotal studies had follow-up durations that were limited. Data for certain groups remain insufficient, particularly regarding long-term use in pediatric populations. In general, the sample sizes were modest in some trials, meaning the research provides context but not individual predictions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Легендаль (FAQ)

Q: Does Легендаль cause drowsiness?

A: According to official product information, this medicine has a negligible influence on the ability to drive or use machinery. This information is generally interpreted as indicating a low likelihood of effects such as drowsiness.

Q: Does Легендаль affect driving?

A: Official regulatory documents state that this medicine has no or negligible influence on a person’s ability to drive safely or operate machinery.

Q: Is it true that Легендаль has a cumulative effect?

A: Official documents describe that several days, typically two to three days, of use may be required before an adequate treatment effect occurs. This indicates a non-immediate onset of action.

Q: What symptoms indicate a possible overdose of Легендаль?

A: The main symptoms reported in official documents following an excessive dose are typically related to the gastrointestinal system. These symptoms include severe diarrhoea, abdominal pain, and potential loss of electrolytes.

Q: How long does it usually take to feel the effect of Легендаль?

A: Official product information states that the effect on bowel regularity may require 24 to 48 hours to occur. This time delay is due to the medicine working primarily in the colon.

Q: Can Легендаль be taken together with other cold medicines?

A: The official documentation on interactions primarily specifies risks with defined drug classes, such as potassium-losing agents. There is no general warning in official documents against the common, non-specific components often found in over-the-counter cold medicines.

Q: Can one drink coffee with Легендаль or can it affect the action?

A: Regulatory documents do not list a specific interaction between the active ingredient and coffee or caffeine. This suggests that the consumption of coffee does not typically interfere with the medicine’s primary actions.

Q: Are there age restrictions for using Легендаль?

A: Use is generally permitted for adults and adolescents aged 14 years and older. Use in children and infants under 14 years for constipation is allowed but requires explicit medical supervision from a healthcare provider.

Q: How long should Легендаль usually be taken?

A: The duration of use is tailored to the individual patient’s response and the condition being managed. Official documentation advises that long-term use of this medicine is inadvisable unless it is conducted under continuous medical supervision.

Q: What interactions of Легендаль with alcohol are described in the instructions?

A: Some flavored formulations of the medicine may contain small, traceable amounts of ethanol (alcohol). This presence requires consideration for specific patient populations, such as pregnant women or those suffering from alcoholism.

Q: Are there special instructions for taking Легендаль for the elderly?

A: Official documents state that no special dosage recommendations exist for elderly patients. However, periodic monitoring of electrolytes is indicated for long-term use (over 6 months).

Q: Can Легендаль be used by children?

A: Use in children and infants under 14 years for constipation is permitted only under the explicit supervision of a healthcare provider. The safety profile for the hepatic encephalopathy indication has not been established in the entire pediatric population.

Q: What do the different dosages of Легендаль mean?

A: Different dosages are used because the medicine treats two different conditions. Lower daily doses are used for general constipation relief, while significantly higher, multi-dose regimens are used and adjusted based on response when treating hepatic encephalopathy (a metabolic condition).

Q: Does food intake affect the absorption of Легендаль?

A: The medicine is poorly absorbed and reaches the colon virtually unchanged, so systemic absorption is not a primary concern. Official product information suggests that if a single daily dose is used, it should be taken at the same time each day to maintain consistency, such as during breakfast.

Q: Are there restrictions on eating grapefruit while taking Легендаль?

A: There is no documented restriction in official regulatory information concerning the consumption of grapefruit or grapefruit juice while taking this medicine.

Q: Does Легендаль affect blood pressure?

A: The medicine may be used with caution in patients with existing conditions like hypertension (high blood pressure) or congestive heart failure. This is noted in documents because of the potential for fluid and electrolyte changes associated with use.

Q: What should I do if Легендаль does not seem to be working?

A: If there is an insufficient therapeutic effect after several days of treatment, the guidance provided in official documents suggests consulting a physician.

Q: Is Легендаль considered safe for long-term use?

A: Long-term use is generally described as inadvisable unless it is conducted under continuous medical supervision. For prolonged use, official documents recommend periodic control of serum electrolytes.

Q: Why is Легендаль sometimes prescribed for such different conditions? (What is its simple mechanism of action?)

A: The medicine is prescribed for different conditions because it has two distinct actions within the body. It works by drawing water into the colon to relieve constipation (osmotic action) and by being broken down by gut bacteria to help the body eliminate ammonia (detoxification).

Q: What warnings about taking Легендаль are in the official documents?

A: Warnings in official documents include cautions for patients with rare hereditary sugar intolerance, diabetic patients, and those with gastro-cardiac syndrome. There are also specific warnings concerning chronic use or misuse of the medicine.

Q: Is it necessary to take Легендаль strictly before meals, or does it not matter?

A: Official product information does not specify that the medicine must be taken strictly before a meal. It recommends that if a single daily dose is used, it should be taken at the same time each day to maintain consistency.

Q: What should I do if I missed a dose of Легендаль?

A: If a dose is missed, instructions generally state to take it as soon as remembered. If it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule resumed. The advice provided is not to double the dose to compensate for a missed one.

Q: How does Легендаль interact with birth control pills?

A: Official documents indicate that if severe diarrhoea or vomiting occurs, the effectiveness of oral contraceptives may be reduced due to the systemic effects of prolonged fluid loss.

How should Легендаль be stored and disposed of?

How to Store and Dispose of Легендаль?

The official storage and disposal requirements for Легендаль (Lactulose solution) are designed to maintain product integrity and ensure environmental safety.

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, typically 20 C to 25 C. Strictly do not freeze and avoid temperatures above 30 C.
Protection	Keep the solution in its original, tightly closed, light-resistant container, away from direct light and excess heat or moisture.
Stability Warning	A normal darkening of color may occur and does not affect the medication. Do not use if extreme darkening or turbidity is present.
Child Safety	As with all medicines, it must be kept out of the sight and reach of children.

Disposal Instructions

Any unused or expired Легендаль must be discarded in accordance with local regulations. It is officially mandated that medicines should not be disposed of via household waste or wastewater (e.g., flushing down the toilet or pouring down the sink).

Легендаль